Connect with us

Hi, what are you looking for?

Tuesday, Feb 27, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Mindset Pharma files patents for non-hallucinogenic, ‘psychedelic-inspired’ drugs

The company believes the drugs have the potential to treat children and seniors

Otsuka Pharmaceutical seals $80M all-cash deal to acquire Mindset Pharma
Photo via Unsplash by Hans Reniers

Toronto-based Mindset Pharma Inc.(CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) wants to patent new drugs that don’t cause any changes in consciousness unlike psilocybin or LSD but have an effect on the same serotonin receptors.

On Wednesday, the drug development company announced it filed two international patent applications under the Patent Cooperation Treaty for the non-tryptamine compounds known as “Family 6″ meant to treat neuropsychiatric and neurological disorders.

The company believes the drugs have the potential to treat a substantially wider patient population such as children or geriatric patients. It says that by reducing or removing the psychedelic effects, in-clinic supervision is not required and therefore, reduces costs and makes it more convenient.

“By applying Mindset’s innovative drug discovery and development platform on novel psychedelic-inspired non-hallucinogenic drug candidates, we have begun to see results,” Mindset Pharma CEO James Lanthier said in a statement.

Read more: Reunion Neuroscience files lawsuit against Mindset Pharma for copying drug compound

Read more: PharmAla and Mindset enter psilocybin distribution agreement

Lanthier says the results of the pre-clinical studies, which form the basis of the patent applications, show great promise. The studies involved testing new drug candidates that are not tryptamines, using methods such as in-vitro screening and studying the absorption, distribution, metabolism and excretion of the drugs in living organisms.

The findings showed that these drug candidates activate the 5-HT2A serotonin receptor, which is associated with certain therapeutic benefits, without causing the typical signs of hallucinogenic effects.

Lanthier said some of these new drugs are more potent than psilocybin and 5-MeO-DMT as 5-HT2A agonists but still do not produce significant hallucinogenic effects, as measured by the lack of head twitch responses observed in the in vivo studies.

Last month, Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) filed a lawsuit alleging that Mindset copied Reunion’s RE104 compound and misleadingly presented that exact composition to the Patent Office. Mindset denies all allegations and plans to defend itself in court.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Medical and Pharmaceutical

Sovereign wealth funds Temasek and Mubadala engage in discussions to finance biotech ventures


Legislation anticipates federal legalization, establishes the Alaska Mental Health and Psychedelics Medicine Task Force


Mind Medicine Australia legally dosed the first patients outside of clinical trials in over 50 years last month


The shipment was received by the medical cannabis company Little Green Pharma and its psychedelics subsidiary